8-K: Actinium Pharmaceuticals Faces NYSE Delisting Risk

Actinium Pharmaceuticals has received a notice of non-compliance from the NYSE American regarding stockholders' equity requirements.

Summary

• Actinium Pharmaceuticals received a notice from the NYSE American indicating non-compliance with Section 1003(a)(ii) of the Company Guide.
• The company failed to maintain the required $4.0 million in stockholders' equity, reporting approximately $2.3 million as of March 31, 2026.
• The company has until June 26, 2026, to submit a compliance plan to the exchange.
• If the plan is accepted, the company has until November 27, 2027, to regain compliance.
• The company's common stock continues to trade under the symbol ATNM with a .BC indicator.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the heightened risk of delisting and the underlying financial instability indicated by the equity shortfall.

Positives

• The company is presenting new data on its ATNM-400 program at the SNMMI 2026 Annual Meeting.
• ATNM-400 has demonstrated potential as a mutation-agnostic, pan-tumor therapy in preclinical models.
• The company maintains a robust intellectual property portfolio with approximately 250 patents and patent applications.

Negatives

• Stockholders' equity of $2.3 million is below the $4.0 million NYSE American minimum requirement.
• The company has reported net losses in each of the last five fiscal years.
• The company is currently ineligible for any exemptions under Section 1003(a) of the Company Guide.

Risks

• Potential delisting from the NYSE American if a compliance plan is not submitted or accepted.
• Risk of failing to meet the November 27, 2027, deadline for regaining compliance.
• Uncertainty regarding the company's ability to secure sufficient capital to meet equity requirements.
• Reliance on successful clinical trial outcomes for future financial viability.

Future Outlook

The company intends to submit a compliance plan to the NYSE American within the required timeframe and continues to advance its clinical pipeline, including ATNM-400, Actimab-A, and Iomab-ACT, with multiple catalysts anticipated in the second half of 2026.

Management Comments

• The company intends to submit a plan to regain compliance within the required timeframe.
• There can be no assurance that the company will be able to achieve compliance with the NYSE American's continued listing standards.

Industry Context

StockSavvy.ai notes that small-cap biotechnology firms frequently face listing compliance challenges due to the high cash burn associated with clinical-stage drug development. The reliance on equity-based financing often leads to volatility in stockholders' equity, making compliance with exchange minimums a common hurdle for the sector.

Comparison to Industry Standards

• The $4.0 million equity threshold is a standard requirement for NYSE American listed companies.
• The company's five-year history of net losses is typical for pre-revenue or early-stage clinical biotechnology companies.

Stakeholder Impact

• Shareholders face increased uncertainty regarding the company's listing status.
• The .BC indicator may impact liquidity and investor sentiment.

Next Steps

• Submit a compliance plan to the NYSE American by June 26, 2026.
• Present ATNM-400 data at the SNMMI 2026 Annual Meeting.
• Await response from the NYSE American regarding the submitted compliance plan.

Key Dates

Recommendation

The combination of persistent net losses and a failure to meet minimum exchange listing requirements signals significant financial distress, making the stock high-risk until a clear path to compliance and funding is established.

Keywords

Actinium Pharmaceuticals, ATNM, NYSE American, Delisting, Radiotherapy, ATNM-400, Stockholders Equity